The dose-response relationship for ashwagandha is not linear
Its time to prioritize ME
flavus , Burkholderia cepacia , various Norcadia species such a N
The STEP 1 trial showed semaglutide 2.4 mg led to 14.9% weight loss over 68 weeks, while SURMOUNT-1 showed tirzepatide achieved up to 20.9% weight reductionapproaching bariatric surgery outcomes.[6] The SELECT trial (17,604 patients) found semaglutide reduced cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% and all-cause mortality by 19%, suggesting direct cardioprotective effects beyond weight loss.[4] In STEP-HFpEF, semaglutide produced 13.3% weight loss in heart failure patients and improved symptoms and physical function
If you are considering a prescription program, you can take the free assessment quiz to see whether a personalized path is a fit for your goals
For a deeper dive into the connection between menopause and weight management, including the role of GLP-1 medications, I encourage you to explore these resources: Menopause and GLP-1s: A Guide to Thriving Through Change Making the Most of Your GLP-1 Menopause Journey Move for Menopause: Exercise Matters on GLP-1s You can also share these articles with your doctor to facilitate a more informed conversation about your options